SCCM Resource Library-BARDA’s Interest in HDTs and Funding Opportunities

BARDA’s Interest in HDTs and Funding Opportunities

Video Transcription

Video Summary

BARDA's 2022 strategic plan emphasizes preparedness, response, partnerships, and workforce, focusing on pathogen-agnostic, host-directed therapeutics to combat severe diseases by FDA approval. The aim is to tackle organ damage, sepsis, and ARDS. BARDA supports advanced and early development through collaborations like CARB-X and Blue Knight with J&J. Challenges include trial complexity, regulatory gaps, and low return on investment. BARDA provides funding, regulatory support, and venture practices, aiming to repurpose and advance precision medicine, and hosts various initiatives for threat-agnostic therapeutics through specific programs and partnerships like DRIVE.

Asset Caption

90-Minute Session | Clinical Evidence for Host-Directed Therapeutics

Meta Tag

Content Type Presentation

Membership Level Professional

Membership Level Select

Year 2024

Keywords

preparedness

therapeutics

partnerships

precision medicine

regulatory support

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.